EU/3/17/1940: Orphan designation for the treatment of haemophilia B
Table of contents
On 12 October 2017, orphan designation (EU/3/17/1940) was granted by the European Commission to Novo Nordisk A/S, Denmark, for concizumab for the treatment of haemophilia B.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in December 2022 on request of the Sponsor.
Treatment of haemophilia B
|Orphan designation status||
|EU designation number||
|Date of designation||
Novo Nordisk A/S
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
|December 2022||The product was withdrawn from the Union Register of orphan medicinal products on request of the Sponsor.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: